Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Torsemide metabolism by CYP2C9 variants and other human CYP2C subfamily enzymes.

× No keyword cloud information.

11 in total

1. Prediction of the effects of genetic polymorphism on the pharmacokinetics of CYP2C9 substrates from in vitro data.

Authors: Makiko Kusama; Kazuya Maeda; Koji Chiba; Akinori Aoyama; Yuichi Sugiyama
Journal: Pharm Res Date: 2008-12-12 Impact factor: 4.200

2. The xenobiotic inhibitor profile of cytochrome P4502C8.

Authors: C E Ong; S Coulter; D J Birkett; C R Bhasker; J O Miners
Journal: Br J Clin Pharmacol Date: 2000-12 Impact factor: 4.335

3. Evaluation of the effect of torsemide on warfarin dosage requirements.

Authors: Sophia Lai; Jeremiah D Momper; Felix K Yam
Journal: Int J Clin Pharm Date: 2017-05-18

4. Cloning of cytochrome P-450 2C9 cDNA from human liver and its expression in CHL cells.

Authors: Ge-Jian Zhu; Ying-Nian Yu; Xin Li; Yu-Li Qian
Journal: World J Gastroenterol Date: 2002-04 Impact factor: 5.742

Review 5. Clinical relevance of genetic polymorphisms in the human CYP2C subfamily.

Authors: J A Goldstein
Journal: Br J Clin Pharmacol Date: 2001-10 Impact factor: 4.335

6. Population Pharmacokinetic (Pop-PK) Analysis of Torsemide in Healthy Korean Males Considering CYP2C9 and OATP1B1 Genetic Polymorphisms.

Authors: Seung-Hyun Jeong; Ji-Hun Jang; Hea-Young Cho; Yong-Bok Lee
Journal: Pharmaceutics Date: 2022-04-01 Impact factor: 6.525

7. Cytochrome P450 2C8 pharmacogenetics: a review of clinical studies.

Authors: Elizabeth B Daily; Christina L Aquilante
Journal: Pharmacogenomics Date: 2009-09 Impact factor: 2.533

8. Identification of the human cytochromes P450 catalysing the rate-limiting pathways of gliclazide elimination.

Authors: David J Elliot; Benjamin C Lewis; Elizabeth M J Gillam; Donald J Birkett; Annette S Gross; John O Miners
Journal: Br J Clin Pharmacol Date: 2007-05-22 Impact factor: 4.335

9. Determinants of steady-state torasemide pharmacokinetics: impact of pharmacogenetic factors, gender and angiotensin II receptor blockers.

Authors: Dierk Werner; Ulrike Werner; Annett Meybaum; Boris Schmidt; Sumaira Umbreen; Anton Grosch; Heiko G Lestin; Bernhard Graf; Oliver Zolk; Martin F Fromm
Journal: Clin Pharmacokinet Date: 2008 Impact factor: 6.447

Review 10. Pharmacogenomics of CYP2C9: Functional and Clinical Considerations.

Authors: Ann K Daly; Allan E Rettie; Douglas M Fowler; John O Miners
Journal: J Pers Med Date: 2017-12-28